Last 7 days
-3.2%
Last 30 days
-4.7%
Last 90 days
2.6%
Trailing 12 Months
-14.0%
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2021Q4 | 2021Q3 |
Revenue | -45.7% | 107 | 198 | 231 | 19.00 | 25.00 |
Operating Expenses | -1.3% | 132 | 134 | 122 | 87.00 | - |
S&GA Expenses | -5.1% | 40.00 | 42.00 | 38.00 | 29.00 | - |
R&D Expenses | 0.5% | 92.00 | 92.00 | 85.00 | 58.00 | - |
EBITDA | 3.6% | 151 | 146 | 253 | - | - |
EBITDA Margin | 90.8% | 1.41* | 0.74* | 1.20* | - | - |
Earnings Before Taxes | 3.6% | 151 | 146 | 155 | -67.48 | - |
EBT Margin | 90.8% | 1.41* | 0.74* | 1.20* | - | - |
Net Income | 7.1% | 111 | 104 | 111 | -65.57 | - |
Net Income Margin | 97.2% | 1.04* | 0.52* | 0.33* | - | - |
Free Cahsflow | -9.4% | -127 | -116 | -43.43 | - | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -9.1% | 561 | 617 | 667 | 437 | 437 |
Current Assets | -18.5% | 474 | 582 | 623 | 322 | 297 |
Cash Equivalents | -35.6% | 156 | 243 | 354 | 76.00 | 60.00 |
Net PPE | 48.2% | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 |
Liabilities | -16.1% | 26.00 | 31.00 | 63.00 | 18.00 | 12.00 |
Current Liabilities | -17.0% | 22.00 | 27.00 | 62.00 | 17.00 | 12.00 |
Shareholder's Equity | -8.7% | 535 | 586 | 605 | 419 | 425 |
Retained Earnings | -128.1% | -47.69 | -20.91 | 4.00 | -171 | -158 |
Additional Paid-In Capital | -4.2% | 585 | 611 | 604 | 593 | 585 |
Accumulated Depreciation | - | 0.00 | - | - | - | - |
Shares Outstanding | 0.1% | 46.00 | 46.00 | 45.00 | 45.00 | 44.00 |
Minority Interest | NaN% | - | - | 0.00 | 1.00 | 0.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -8.4% | -126 | -116 | -73.05 | -63.83 | -43.43 |
Share Based Compensation | -14.2% | 28.00 | 33.00 | 32.00 | 27.00 | 24.00 |
Cashflow From Investing | -4.9% | 249 | 262 | 294 | -161 | -333 |
Cashflow From Financing | -367.9% | -25.93 | 10.00 | 9.00 | 8.00 | 269 |
88.8%
88.8%
72.4%
Y-axis is the maximum loss one would have experienced if Cullinan Oncology was unfortunately bought at previous high price.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | unchanged | - | -95,111 | 442,889 | -% |
2023-02-28 | Voya Investment Management LLC | unchanged | - | -27,435 | 129,565 | -% |
2023-02-21 | MACQUARIE GROUP LTD | sold off | - | -14,000 | - | -% |
2023-02-15 | ALLIANCEBERNSTEIN L.P. | added | 5.62 | -44,490 | 297,510 | -% |
2023-02-15 | Tejara Capital Ltd | new | - | 248,980 | 248,980 | 0.14% |
2023-02-15 | Metropolitan Life Insurance Co/NY | added | 8.52 | -2,048 | 20,952 | -% |
2023-02-15 | MetLife Investment Management, LLC | reduced | -17.42 | -81,716 | 173,284 | -% |
2023-02-15 | Annandale Capital, LLC | unchanged | - | -22,000 | 106,000 | 0.04% |
2023-02-14 | Aquatic Capital Management LLC | new | - | 75,000 | 75,000 | -% |
2023-02-14 | SVB FINANCIAL GROUP | new | - | 285,188 | 285,188 | 0.78% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 15, 2023 | jovan-embiricos morana | 3.4% | 1,577,440 | SC 13G/A | |
Feb 14, 2023 | biotechnology value fund l p | 8.9% | 4,058,854 | SC 13G/A | |
Feb 13, 2023 | chi advisors llc | 7.25% | 3,317,544 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 6.15% | 2,812,965 | SC 13G/A | |
Feb 03, 2023 | blackrock inc. | 5.5% | 2,506,215 | SC 13G | |
Feb 14, 2022 | biotechnology value fund l p | 6.4% | 2,790,018 | SC 13G/A | |
Feb 11, 2022 | foresite capital fund v, l.p. | 2.6% | 1,143,006 | SC 13G/A | |
Feb 11, 2022 | chi advisors llc | 5.67% | 2,476,720 | SC 13G | |
Feb 09, 2022 | vanguard group inc | 5.42% | 2,366,808 | SC 13G |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 09, 2023 | 10-K | Annual Report | |
Mar 09, 2023 | 8-K | Current Report | |
Mar 09, 2023 | S-3 | S-3 | |
Mar 09, 2023 | S-8 | Employee Benefits Plan | |
Mar 09, 2023 | S-8 | Employee Benefits Plan | |
Feb 23, 2023 | 4 | Insider Trading | |
Feb 21, 2023 | 4 | Insider Trading | |
Feb 21, 2023 | 4 | Insider Trading | |
Feb 21, 2023 | 4 | Insider Trading | |
Feb 21, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-02-22 | AHMED NADIM | acquired | - | - | 109,000 | president and ceo |
2023-02-17 | Michaelson Jennifer | acquired | - | - | 38,500 | chief development officer |
2023-02-17 | Trigilio Jeffrey | acquired | - | - | 47,000 | chief financial officer |
2023-02-17 | Jones Jeffrey Alan | acquired | - | - | 60,000 | chief medical officer |
2023-02-17 | SUMER JACQUELYN L | acquired | - | - | 47,000 | chief legal officer |
2023-02-17 | Baeuerle Patrick | acquired | - | - | 38,500 | chief scientific officer |
2023-02-17 | Savill Corrine | acquired | - | - | 20,500 | chief business officer |
2023-01-19 | BVF PARTNERS L P/IL | sold | - | - | -6,400,000 | - |
2022-12-30 | Trigilio Jeffrey | acquired | 1,802 | 8.97 | 201 | chief financial officer |
2022-11-25 | Michaelson Jennifer | sold | -53,200 | 13.3 | -4,000 | see remarks |
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | |
Income Statement [Abstract] | ||
Revenue | $ 0 | $ 18,943 |
Type of revenue [Extensible List] | us-gaap:LicenseMember | us-gaap:LicenseMember |
Operating expenses: | ||
Research and development | $ 91,948 | $ 57,751 |
General and administrative | 40,189 | 29,146 |
Total operating expenses | 132,137 | 86,897 |
Gain on sale of Cullinan Pearl | 276,785 | 0 |
Income (loss) from operations | 144,648 | (67,954) |
Other income (expense): | ||
Interest income | 6,611 | 477 |
Other income (expense), net | 57 | (8) |
Net income (loss) before income taxes | 151,316 | (67,485) |
Income tax expense | 42,121 | 0 |
Net income (loss) | 109,195 | (67,485) |
Net loss attributable to noncontrolling interest | (2,019) | (1,915) |
Net income (loss) attributable to common stockholders of Cullinan | 111,214 | (65,570) |
Comprehensive income (loss): | ||
Net income (loss) | 109,195 | (67,485) |
Unrealized loss on investments | (1,763) | (836) |
Comprehensive income (loss) | 107,432 | (68,321) |
Comprehensive loss attributable to noncontrolling interest | (2,019) | (1,915) |
Comprehensive income (loss) attributable to Cullinan | $ 109,451 | $ (66,406) |
Earnings (net loss) per share: | ||
Earnings Per Share, Basic | $ 2.46 | $ (1.52) |
Earnings Per Share, Diluted | $ 2.38 | $ (1.52) |
Weighted-average shares used in computing earnings (net loss) per share: | ||
Weighted Average Number of Shares Outstanding, Basic | 45,164 | 43,077 |
Weighted Average Number of Shares Outstanding, Diluted | 46,640 | 43,077 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 156,152 | $ 59,774 |
Short-term investments | 311,140 | 230,692 |
Prepaid expenses and other current assets | 7,180 | 6,098 |
Total current assets | 474,472 | 296,564 |
Property and equipment, net | 1,174 | 77 |
Operating lease right-of-use assets | 4,130 | 0 |
Other assets | 459 | 147 |
Long-term investments | 80,882 | 140,397 |
Total assets | 561,117 | 437,185 |
Current liabilities: | ||
Accounts payable | 2,660 | 3,169 |
Accrued expenses and other current liabilities | 14,135 | 8,577 |
Income tax payable | 4,282 | |
Operating lease liabilities, current | 1,421 | |
Total current liabilities | 22,498 | 11,746 |
Long-term liabilities: | ||
Lease liabilities, non-current | 3,590 | |
Deferred rent | 0 | 65 |
Total liabilities | 26,088 | 11,811 |
Commitments and contingencies (Note 12) | ||
Stockholders' equity: | ||
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of December 31, 2022 and 2021; no shares issued and outstanding as of December 31, 2022 and 2021, respectively. | ||
Common stock, $0.0001 par value, 150,000,000 shares authorized as of December 31, 2022 and 2021; 45,796,449 and 44,292,102 shares issued and outstanding as of December 31, 2022 and 2021, respectively. | 5 | 4 |
Additional paid-in capital | 585,320 | 584,714 |
Accumulated other comprehensive loss | (2,601) | (838) |
Accumulated deficit | (47,695) | (158,909) |
Total Cullinan stockholders' equity | 535,029 | 424,971 |
Noncontrolling interests | 0 | 403 |
Total stockholders' equity | 535,029 | 425,374 |
Total liabilities and stockholders' equity | $ 561,117 | $ 437,185 |